The focus of cancer immunotherapies is, by leveraging the immune system, to utilize the natural immunity to fight with cancer. Compared with traditional therapies, monoclonal antibody-based immunotherapy is thought to be more advantageous. As a thriving CRO, Creative Biolabs Next-IO™ team is dedicated to developing and accelerating novel therapeutic mAb programs with the hope of our partners. This anti-KIR2DL4 mAb program aims to develop therapeutic mAb against KIR2DL4 that could potentially restore the cytotoxicity activity of NK cells. Learn more: kir2dl4 antibody program
